tooyes tirzepatide F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Tirzepatide Weight Loss Injections |

- What is the exact patient population in need for the combination

Coverage Baseline Previously unavailable under Medicare Part D Only 13 states cover them in Medicaid (KFF HMA survey) 19% of large employers cover GLP-1s for obesity, though 43% of employers with 5,000+ employees offer coverage (KFF 2025 survey) Current Expansion ~50% of CVS Caremark clients now provide coverage for weight loss Medicare GLP-1 Bridge program launches coverage for eligible Medicare Part D patients 7/1/26 This aligns with a recent survey from Business Group on Health that found 67% of the surveyed employers now cover GLP-1s for weight loss (though a reduction is expected for 2027)

As patents for Semaglutide begin to expire, we are moving from a period of high-cost exclusivity to a new era of mass accessibility

Lifestyle interventions, including dietary changes and structured exercise programs, may be associated with benefits in terms of functional capacity and symptom burden, and retrospective cohort studies of surgical weight loss have raised the possibility of improvements in medium term survival for patients with baseline HF, challenging the previous notions of the "obesity survival paradox